Log in

NASDAQ:HARPHarpoon Therapeutics Stock Price, Forecast & News

$13.68
+0.30 (+2.24 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.42
Now: $13.68
$14.27
50-Day Range
$11.01
MA: $14.81
$18.21
52-Week Range
$10.27
Now: $13.68
$25.02
Volume291,145 shs
Average Volume146,140 shs
Market Capitalization$343.94 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
Phone650-443-7400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.78 million
Book Value$3.82 per share

Profitability

Net Income$-55,570,000.00
Net Margins-571.20%

Miscellaneous

Employees45
Market Cap$343.94 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$13.68
+0.30 (+2.24 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

How has Harpoon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has increased by 4.7% and is now trading at $13.68.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Harpoon Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Harpoon Therapeutics
.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Harpoon Therapeutics
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics Inc (NASDAQ:HARP) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.04. Harpoon Therapeutics had a negative return on equity of 62.20% and a negative net margin of 571.20%.
View Harpoon Therapeutics' earnings history
.

What price target have analysts set for HARP?

7 equities research analysts have issued twelve-month price targets for Harpoon Therapeutics' shares. Their forecasts range from $25.00 to $38.00. On average, they anticipate Harpoon Therapeutics' stock price to reach $30.57 in the next year. This suggests a possible upside of 123.5% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics
.

Has Harpoon Therapeutics been receiving favorable news coverage?

News coverage about HARP stock has trended negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Harpoon Therapeutics earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Harpoon Therapeutics
.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a drop in short interest in February. As of February 15th, there was short interest totaling 251,600 shares, a drop of 28.3% from the January 31st total of 351,000 shares. Based on an average daily volume of 141,000 shares, the short-interest ratio is presently 1.8 days. Approximately 1.8% of the company's stock are sold short.
View Harpoon Therapeutics' Short Interest
.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Dr. Luke B. Evnin, Chairman (Age 56)
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Bessemer Group Inc. (0.13%), Russell Investments Group Ltd. (0.09%), Virtus ETF Advisers LLC (0.08%), Virtu Financial LLC (0.05%), Strs Ohio (0.05%) and New York State Common Retirement Fund (0.04%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle.
View institutional ownership trends for Harpoon Therapeutics
.

Which institutional investors are selling Harpoon Therapeutics stock?

HARP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks, and Patrick Baeuerle.
View insider buying and selling activity for Harpoon Therapeutics
.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Virtus ETF Advisers LLC, Virtu Financial LLC, Strs Ohio, New York State Common Retirement Fund, and Russell Investments Group Ltd.. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, and Luke Evnin.
View insider buying and selling activity for Harpoon Therapeutics
.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $13.68.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $343.94 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.